Controversy About Management of Osteoarthritis with Disease-modifying Anti-rheumatic Drugs
Osteoarthritis (OA) is a degenerative joint cartilage disease characterized pathologically by osteophytes formation and subchondral bone damage. It leads to pain, stiffness, deformation and even disability in the patients, and increases the risk of comorbidities. As its pathophysiological mechanisms...
Saved in:
Main Authors: | CUI Hanshu, LIU Bin |
---|---|
Format: | Article |
Language: | zho |
Published: |
Editorial Office of Medical Journal of Peking Union Medical College Hospital
2025-01-01
|
Series: | Xiehe Yixue Zazhi |
Subjects: | |
Online Access: | https://xhyxzz.pumch.cn/article/doi/10.12290/xhyxzz.2024-0802 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Myeloid-related proteins 8/14 failed to act as theragnostic biomarker in axial spondyloarthritis patients on combination disease-modifying anti-rheumatic drugs therapy
by: Arvind Ganapati, et al.
Published: (2020-01-01) -
Spondyloarthritis and Risk of Malignancy: A Narrative Review on a Still Controversial Issue
by: Ennio Giulio Favalli, et al.
Published: (2024-12-01) -
Heat therapy in rheumatic and musculoskeletal diseases – an overview of clinical and molecular effects
by: Philipp Klemm, et al.
Published: (2024-12-01) -
Primer on the Rheumatic Diseases /
Published: (1993) -
Efficacy and safety of conventional synthetic, biologic, and targeted synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis-interstitial lung disease: A narrative review
by: Richard Conway, et al.
Published: (2021-01-01)